May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Minimally Classic or Occult With No Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration Treated by an Alternative Regimen of Intravitreal Bevacizumab: Bemino Study
Author Affiliations & Notes
  • R. B. Dichtchekenian
    Retina, Hospital Otalmologico de Sorocaba, Sorocaba, Brazil
  • L. T. Dalfre
    Retina, Hospital Otalmologico de Sorocaba, Sorocaba, Brazil
  • G. Z. Ramos
    Retina, Hospital Otalmologico de Sorocaba, Sorocaba, Brazil
  • V. C. C. Afonso
    Retina, Hospital Otalmologico de Sorocaba, Sorocaba, Brazil
  • A. F. Bordon
    Retina, Hospital Otalmologico de Sorocaba, Sorocaba, Brazil
  • Footnotes
    Commercial Relationships  R.B. Dichtchekenian, None; L.T. Dalfre, None; G.Z. Ramos, None; V.C.C. Afonso, None; A.F. Bordon, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 330. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. B. Dichtchekenian, L. T. Dalfre, G. Z. Ramos, V. C. C. Afonso, A. F. Bordon; Minimally Classic or Occult With No Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration Treated by an Alternative Regimen of Intravitreal Bevacizumab: Bemino Study. Invest. Ophthalmol. Vis. Sci. 2008;49(13):330. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The primary objectives are to evaluate the visual acuity (VA) and ocular coherence tomography (OCT) macular thickness changes with the use of intravitreous bevacizumab (IVB) in the treatment of minimally classic (MC) or occult with no classic (ONC) subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The secondary objective is to evaluate safety of this procedure.

Methods: : This is an open-label, prospective, non-randomized, non-controlled, interventional, consecutive case series. Patients with MC or ONC due to AMD were enrolled. Patients were treated with 2.0mg IVB at baseline, 3 months, 6 months, 9 months, and 12 months. VA was measured using the ETDRS chart. OCT was performed at baseline and at each follow-up visit. Patients with follow-up shorter than 3 months were excluded from this analysis. Fluorescein angiograms were performed at baseline, 45 days, 90 days, and every 3 months thereafter.

Results: : We included 7 eyes of 7 patients. Five were male. Three were right eyes. Mean age was 72.4 years-old (56-84 yr-old). Mean follow-up was 201.2 days (90-360 days). Five patients were MC and 2 patients were ONC. Mean best-corrected visual acuity was 1.24, 1.15, 1.06, 1.03 and 1.15 logMAR units at baseline, 3 months, 6 months, 9 months and 12 months, respectively. No patient experienced loss of VA during follow-up. Mean OCT macular thickness was 307.2µm, 296.7µm, 266µm, 240.3µm and 229µm at baseline, 3 months, 6 months, 9 months and 12 months, respectively. No ocular or systemic adverse effect occurred during the follow-up period.

Conclusions: : In a mean follow-up of 201.2 days, 2.0mg of bevacizumab injected every 3 months stabilized or improved VA in patients with MC or ONC due to AMD and was safe throughout the study.

Keywords: retina • age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×